Venetoclax / Venclexta (Everest)

Product Overview

Venetoclax (also known as Venetoclax; Brand name: Venclexta) is the world’s first selective BCL-2 (B-cell lymphoma-2) inhibitor developed for the treatment of certain blood cancers and hematologic malignancies.

In many blood cancers, the BCL-2 protein helps cancer cells survive by blocking the natural process of programmed cell death (apoptosis). Venetoclax works by selectively inhibiting the BCL-2 protein, restoring the cell’s ability to undergo apoptosis and promoting the destruction of malignant cells.

Venetoclax was jointly developed by AbbVie and Genentech (a member of the Roche Group). It received initial approval in April 2016 for the treatment of chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and acute myeloid leukemia (AML).

In May 2019, the U.S. FDA approved Venetoclax in combination with obinutuzumab as a first-line treatment option for CLL/SLL.

📊 Clinical Study Highlights

In the Phase 1b M14-358 clinical trial:

Venetoclax + Azacitidine

• Complete Remission (CR) rate: 44%
• CR + CRi rate: 71%
• Median duration of response: 21.9 months
• Median time to first CR/CRi: 1.2 months

Venetoclax + Decitabine

• CR rate: 55%
• CR + CRi rate: 74%
• Median duration of response: 15 months
• Median time to first CR/CRi: 1.9 months

These findings demonstrated significant response rates and durable remission benefits in AML patients.

💡 Clinical Importance in AML

As a once-daily oral therapy, Venetoclax blocks BCL-2 activity, helping eliminate malignant blood cells while reducing reliance on intensive chemotherapy.

The UK National Institute for Health and Care Excellence (NICE) recommended Venetoclax combined with azacitidine for the treatment of AML patients unsuitable for intensive chemotherapy, citing improved overall survival, rapid and durable remission, and reduced dependence on blood transfusions.

AML is an aggressive and difficult-to-treat blood cancer with historically poor survival outcomes. Many newly diagnosed elderly patients are unable to tolerate standard intensive induction chemotherapy due to age and underlying health conditions.

Compared with traditional hospital-based treatments, oral Venetoclax-based therapy may help reduce hospitalization frequency and transfusion dependence, potentially improving quality of life for patients.

Professor Charlie Craddock, Director of the Centre for Clinical Haematology at Queen Elizabeth Hospital Birmingham, described Venetoclax plus azacitidine as one of the most important advances in AML treatment for patients unfit for intensive chemotherapy in more than 30 years.

📌 Approved Indications

Venetoclax is approved for:

1. Chronic lymphocytic leukemia (CLL) with chromosome 17p deletion
2. Second-line treatment of CLL/SLL in combination with rituximab
3. First-line treatment of acute myeloid leukemia (AML) in combination with azacitidine, decitabine, or low-dose cytarabine for patients unsuitable for standard induction chemotherapy

💊 Dosage and Administration

Venetoclax uses a gradual weekly dose escalation schedule to reduce the risk of tumor lysis syndrome (TLS):

• Continue treatment until disease progression or unacceptable toxicity occurs
• Take once daily at approximately the same time with food and water
• Swallow tablets whole; do not chew, crush, or break tablets

⚠️ Common Side Effects

Common adverse reactions (≥20%) may include:

• Neutropenia
• Diarrhea
• Nausea
• Anemia
• Upper respiratory tract infections
• Thrombocytopenia
• Fatigue

🚫 Contraindications

During the initiation and dose-escalation phase, Venetoclax should not be used together with strong CYP3A inhibitors due to the increased risk of severe toxicity.

📦 Storage and Handling

• Store in the original packaging
• Do not remove the desiccant packet
• Protect from moisture and direct light
• Store at or below 30°C (86°F)